What is Invizius?
Invizius Limited operates at the intersection of immunology and medical device technology. The company is primarily engaged in the development of novel therapeutic agents that suppress the body's unwanted innate immune responses. Its lead programs are specifically targeted at reducing the life-threatening inflammatory effects experienced by patients undergoing dialysis. By modulating the immune system's reaction to medical interventions, Invizius aims to improve patient outcomes and reduce the systemic burden of chronic inflammatory conditions. The firm's position as a late pre-clinical-stage entity highlights its transition from foundational research toward rigorous clinical validation, a critical phase for any high-growth biotech enterprise.
How much funding has Invizius raised?
Invizius has raised a total of $8.6M across 2 funding rounds:
Series A
$7.4M
Other Financing Round
$1.2M
Series A (2021): $7.4M with participation from Scottish Enterprise, Dr. Jonathan Milner, Mercia Group, Solvay Ventures, Downing Ventures, Old College Capital, and Calculus Capital
Other Financing Round (2024): $1.2M led by Calculus Capital and Mercia Ventures
Key Investors in Invizius
Calculus Capital
Calculus Capital is a London-based investment manager specializing in tax-efficient growth capital for UK smaller companies, focusing on high-growth technology and healthcare sectors.
Downing Ventures
Downing Ventures is an evergreen fund that invests in seed to Series A companies across various technology sectors, including healthcare, deep tech, and enterprise solutions.
Scottish Enterprise
Scottish Enterprise is a national economic development agency and non-departmental public body of the Scottish Government, dedicated to fostering innovation and economic growth.
What's next for Invizius?
With the recent influx of capital, Invizius is expected to prioritize the advancement of its lead candidates through the regulatory and clinical trial landscape. The strategic focus will likely center on scaling manufacturing processes and preparing for human clinical trials, which are essential for validating the efficacy of their immune-suppression technology. As the company matures, it will likely seek to expand its intellectual property portfolio and explore potential partnerships with established medical device manufacturers to integrate its solutions into existing dialysis infrastructure. This phase of development is pivotal, as the company moves to demonstrate that its therapeutic approach can significantly improve the quality of life for patients suffering from chronic renal failure.
See full Invizius company page
